Atlas Trials

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Clinical trial NCT03420508 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03420508
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2018-01-10
Primary completion
2027-01-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.